Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives

Core Viewpoint - Vincerx Pharma, Inc. has terminated its previously signed binding Term Sheet for a reverse merger transaction with Oqory, Inc. and Vivasor, Inc. [1] Group 1: Strategic Alternatives - The board of directors will reassess the Company's strategic alternatives, which may include out-licensing, merger and acquisition opportunities (including reverse mergers), sale of assets and technologies, and winding down operations [2] - The Company had approximately $3.9 million in cash as of February 26, 2025, with an expected cash runway extending through late Q2 2025 [2]